Vitamin D Supplementation: Critical Findings in 4 Subgroups
Evidence synthesis from VITAL, DO-HEALTH, and D-Health on who truly benefits from vitamin D supplementation in primary care.
One-Minute Takeaway on Vitamin D Supplementation
One-Minute Takeaway
- Vitamin D supplementation in unselected, mostly vitamin D-replete adults shows little to no benefit for cancer, cardiovascular disease, fractures, or all-cause mortality based on the VITAL, DO-HEALTH, and D-Health trials enrolling nearly 50,000 participants.
- DO-HEALTH found 2,000 IU/day did not significantly reduce falls, non-vertebral fractures, blood pressure, infection rate, or cognitive decline in adults aged ≥70.
- High-dose intermittent regimens (annual or large monthly boluses) have been associated with increased falls and fractures — not reduced.
- Specific subgroups likely benefit: vitamin D-deficient individuals, pregnant women, exclusively breastfed infants, and adults with documented osteomalacia or malabsorption.
- The USPSTF gives an “I” statement (insufficient evidence) for routine 25(OH)D screening of asymptomatic adults; targeted screening of high-risk groups is more defensible.
Why Vitamin D Supplementation Matters in Primary Care
Few interventions in family medicine have grown faster, or with weaker evidence support, than vitamin D supplementation. US sales exceed one billion dollars annually, and 25(OH)D testing has expanded dramatically over the past two decades despite repeated recommendations against routine screening.
Until recently, the major question — does vitamin D supplementation prevent disease in unselected adults — had been answered largely by observational data showing low 25(OH)D levels associated with cardiovascular disease, cancer, autoimmune conditions, infection, and mortality. These associations propelled clinical enthusiasm well ahead of randomized evidence.
VITAL, DO-HEALTH, and D-Health collectively reframed clinical thinking. They tested moderate to monthly daily-equivalent doses against meaningful clinical endpoints in well-powered cohorts, and the headline results have been largely null for cancer, cardiovascular disease, fractures, falls in community-dwelling adults, and all-cause mortality.
For family physicians, the practical task has shifted from “should I prescribe vitamin D supplementation?” to “in whom does vitamin D supplementation actually deliver benefit, and in whom does it amount to medicalized placebo?” This evidence review organizes the answer around four subgroups.
What Evidence Was Reviewed
This synthesis draws on three landmark prevention trials (VITAL with its prespecified fracture analysis, DO-HEALTH, and D-Health), the D2d diabetes prevention trial, two pivotal high-dose harm-signal trials, recent systematic reviews and meta-analyses with trial sequential analysis, and current USPSTF recommendations on screening and supplementation.
The table below summarizes the key evidence sources informing the comparative claims in this review.
| Study / Review | Design | n | Population | Intervention | Primary Outcome |
|---|---|---|---|---|---|
| VITAL (Manson 2019) | RCT, 2×2 factorial | 25,871 | US men ≥50, women ≥55 | Vitamin D3 2,000 IU/d ± ω-3 | Invasive cancer + major CVD events |
| VITAL Fracture (LeBoff 2022) | Prespecified analysis | 25,871 | Same as VITAL | Vitamin D3 2,000 IU/d | Total, hip, non-vertebral fractures |
| DO-HEALTH (Bischoff-Ferrari 2020) | RCT, 2×2×2 factorial | 2,157 | European adults ≥70 | Vit D3 2,000 IU/d ± ω-3 ± exercise | BP, cognition, infection, falls, fracture |
| D-Health (Neale 2022) | RCT | 21,315 | Australian adults 60–84 | 60,000 IU/month vitamin D3 | All-cause mortality |
| D2d (Pittas 2019) | RCT | 2,423 | Adults with prediabetes | 4,000 IU/d vitamin D3 | Incident type 2 diabetes |
| Bolland 2018 | SR / MA + trial sequential analysis | ~81 trials | Mixed adult populations | Vitamin D various | Fracture, falls, BMD |
| Bischoff-Ferrari 2016 | RCT, 3-arm | 200 | Adults ≥70 with prior fall | 60,000 vs 24,000 IU/month + calcifediol | Lower-extremity function, falls |
| Sanders 2010 (WHI annual) | RCT | 2,256 | Older community women | 500,000 IU annually | Falls and fractures |
| USPSTF 2018 (supplementation) | Recommendation | — | Community-dwelling adults | Vitamin D ± calcium | Primary fracture prevention |
| USPSTF 2021 (screening) | Recommendation | — | Asymptomatic adults | 25(OH)D screening | Health outcomes from screening |
Key Findings on Vitamin D Supplementation Across Subgroups
Subgroup 1 — General Replete Adults: Minimal Benefit on Major Outcomes
VITAL randomized 25,871 US adults to 2,000 IU/day cholecalciferol or placebo for a median of 5.3 years. The trial reported no significant reduction in invasive cancer (HR 0.96, 95% CI 0.88–1.06) or major cardiovascular events (HR 0.97, 95% CI 0.85–1.12) in the overall population.
The prespecified VITAL fracture analysis (LeBoff 2022) found no reduction in total, hip, or non-vertebral fractures (HR for total fracture 0.98, 95% CI 0.89–1.08). D-Health randomized 21,315 Australian adults to 60,000 IU/month and reported no significant effect on all-cause mortality (HR 1.04, 95% CI 0.93–1.18).
Across these and supporting Cochrane meta-analyses, vitamin D supplementation in unselected, largely vitamin D-replete adults does not meaningfully alter risk of cancer, cardiovascular disease, all-cause mortality, or fragility fracture.
Subgroup 2 — Older Adults at Fall and Fracture Risk: Mixed Signals, Possible Harm at High Doses
Earlier Cochrane reviews suggested vitamin D may modestly reduce falls in older adults, particularly those who were vitamin D-deficient at baseline. More recent high-dose trials have added an important caveat: Bischoff-Ferrari 2016 (60,000 IU monthly) and Sanders 2010 (500,000 IU annually in the WHI Annual trial) both reported increased falls or fractures with intermittent supraphysiologic dosing.
DO-HEALTH provided contemporary factorial-design analysis of 2,157 European adults aged ≥70 and found 2,000 IU/day vitamin D supplementation alone did not significantly reduce non-vertebral fractures, falls, blood pressure, or rate of cognitive decline over three years.
The 2018 USPSTF concluded that current evidence is insufficient to assess balance of benefits and harms of vitamin D supplementation for fall and fracture prevention in community-dwelling adults at average risk. Daily moderate dosing (800–2,000 IU) appears safe, but routine prescribing for prevention in non-deficient community-dwelling adults is not strongly evidence-supported.
Clinical pearl on vitamin D supplementation dosing: Annual mega-doses (≥500,000 IU) and very high monthly boluses (≥60,000 IU) carry harm signals for falls and fractures. When supplementation is indicated, daily moderate dosing aligned with biological need is the more defensible approach.
Subgroup 3 — Pregnancy, Infants, and Severe Deficiency: Clearer Benefit
Three populations show more consistent evidence of benefit from vitamin D supplementation:
Vitamin D-deficient adults: Individuals with baseline 25(OH)D below 30 nmol/L (12 ng/mL) show consistent benefit from supplementation for bone mineral density, calcium homeostasis, and prevention of osteomalacia. The metabolic logic is straightforward — replenishing severe deficiency restores normal mineralization.
Pregnancy: Pooled trial evidence indicates vitamin D supplementation during pregnancy is associated with reduced risk of pre-eclampsia, gestational diabetes, low birth weight, and small-for-gestational-age infants, although effect sizes are modest and certainty of evidence varies by outcome.
Exclusively breastfed infants: AAP and equivalent guideline bodies recommend 400 IU/day for breastfed infants from the first days of life. Evidence supporting prevention of nutritional rickets in this population is robust and uncontroversial — this is a population in which vitamin D supplementation has clear, established benefit.
Subgroup 4 — Routine Screening of Asymptomatic Adults: Insufficient Evidence
The 2021 USPSTF assigned an “I” statement (insufficient evidence) for screening asymptomatic adults for vitamin D deficiency. The Endocrine Society and several other bodies recommend targeted screening of high-risk groups only — including malabsorption, chronic kidney disease, granulomatous disease, certain medications, and dark-skinned individuals with limited sun exposure.
Practical issues complicate population-wide screening strategies. Assay variability remains substantial across commercial laboratories, the definition of “deficiency” itself is contested (50 vs 75 nmol/L thresholds), and reverse causation in observational data may explain part of the apparent association between low 25(OH)D and adverse outcomes.
VITAL was a placebo-controlled, 2×2 factorial RCT enrolling 25,871 US men aged ≥50 and women aged ≥55, randomized to vitamin D3 2,000 IU/day, marine omega-3 fatty acids 1 g/day, both, or neither. Median follow-up was 5.3 years.
Headline findings:
- Cancer (overall): No significant reduction in invasive cancer.
- Cardiovascular disease: No significant reduction in major events.
- Fractures (LeBoff 2022): No significant reduction in total, hip, or non-vertebral fractures.
- Subgroup signals: Possible reduced cancer mortality in extended follow-up, and reduced advanced cancer incidence in normal-BMI participants and Black participants — hypothesis-generating only.
VITAL was not designed to test vitamin D in deficient individuals; baseline 25(OH)D averaged ~31 ng/mL, and the trial does not directly inform supplementation in deficient populations.
DO-HEALTH was a 2×2×2 factorial RCT of 2,157 community-dwelling European adults aged ≥70 randomized to vitamin D3 2,000 IU/day, omega-3 1 g/day, and a strength-training exercise program — alone, in combination, or none. Follow-up was 3 years.
For the vitamin D supplementation comparison alone, none of the prespecified primary outcomes — systolic blood pressure, Short Physical Performance Battery, Montreal Cognitive Assessment, infection rate, or non-vertebral fracture — reached statistical significance versus the no-vitamin-D comparison.
DO-HEALTH does not refute benefit in deficient individuals — but it provides strong evidence that adding 2,000 IU/day in generally replete community-dwelling adults aged ≥70 is unlikely to deliver meaningful effect on the outcomes families and physicians most care about.
D-Health randomized 21,315 Australian adults aged 60–84 to 60,000 IU vitamin D3 monthly or matching placebo for a planned 5 years. Median follow-up was 5.7 years.
The trial reported no significant difference in all-cause mortality (HR 1.04, 95% CI 0.93–1.18). Cancer mortality showed a modest non-significant elevation in a secondary analysis, while cardiovascular mortality was numerically lower — neither finding altered the headline conclusion.
The monthly dosing approach in D-Health raises a parallel question to the harm-signal trials at higher monthly and annual doses: 60,000 IU monthly is a supraphysiologic bolus, and whether daily equivalent dosing would have produced different outcomes cannot be answered from this trial.
The D2d trial randomized 2,423 adults with prediabetes to 4,000 IU/day vitamin D3 or placebo. Over 2.5 years median follow-up, the rate of progression to type 2 diabetes was not significantly reduced overall (HR 0.88, 95% CI 0.75–1.04).
Post hoc subgroup analyses suggested possible benefit in participants with baseline 25(OH)D below 12 ng/mL, but the overall trial was negative for the primary outcome and is best interpreted as not supporting routine vitamin D supplementation for diabetes prevention in adults with prediabetes who are not severely deficient.
The USPSTF 2021 review found inadequate evidence that screening asymptomatic adults for vitamin D deficiency improves clinical outcomes — separate from the question of whether supplementation in deficient individuals helps. Three issues drove the conclusion:
- Lack of consensus on the threshold defining “deficiency” — 50 nmol/L (Institute of Medicine) versus 75 nmol/L (Endocrine Society) substantially changes population prevalence.
- Substantial inter-assay variability in commercial 25(OH)D testing.
- Limited trial evidence that screening-and-treating strategies improve patient-important outcomes versus targeted treatment of clinically suspected deficiency.
Targeted screening of high-risk groups remains evidence-aligned and is endorsed by multiple specialty bodies.
Quality & Consistency of Evidence on Vitamin D Supplementation
The evidence base for vitamin D supplementation in disease prevention is unusually mature for a nutritional intervention, with three large, contemporary RCTs converging on similar conclusions for unselected adults. Consistency varies meaningfully across outcomes and subgroups.
What the Evidence on Vitamin D Supplementation Does Not Show
Several specific gaps remain in the vitamin D supplementation evidence base. Naming them clearly helps clinicians counsel patients honestly and identify where ongoing research will refine practice.
Specific Evidence Gaps
- Severe deficiency outcomes: The major prevention trials largely excluded participants with 25(OH)D below 30 nmol/L; benefit in this population is extrapolated rather than directly trial-tested.
- Optimal dose-response curve: The shape of the dose-response between vitamin D supplementation and bone or non-skeletal outcomes across baseline 25(OH)D levels remains poorly characterized.
- Active forms versus cholecalciferol: Calcitriol, calcifediol, and other activated forms are inadequately compared to standard vitamin D3 in primary prevention contexts.
- Race and ethnicity-specific effects: VITAL signaled potential cancer benefit in Black participants; these findings are hypothesis-generating and require dedicated replication.
- Pregnancy outcome heterogeneity: Trials in pregnancy vary substantially in baseline status, dose, timing, and primary endpoint, limiting definitive conclusions on optimal regimens.
- Skeletal extremes: Patients with osteomalacia, post-bariatric surgery, malabsorption, and chronic kidney disease are underrepresented in major prevention trials.
- Fall risk mechanisms: Whether vitamin D affects fall risk via muscle, balance, or cognitive pathways is not well characterized, complicating intervention targeting.
- Long-term post-trial outcomes: Latent effects on cancer or autoimmune disease incidence beyond 5 years are not yet adequately captured in VITAL or D-Health follow-up.
- Combined vitamin D and calcium effects: Trial designs rarely permit clean separation of vitamin D supplementation effects from concurrent calcium intake, limiting precise effect estimation.
Practical Implications
Based on the current evidence on vitamin D supplementation, the following considerations may help structure prescribing and counseling decisions in family practice. These are framed as evidence-supported considerations rather than directive recommendations.
Evidence Supports Targeted Supplementation in Documented Deficiency
25(OH)D below 30 nmol/L (12 ng/mL) carries a clearer indication for cholecalciferol replacement. Daily moderate-dose regimens (1,000–2,000 IU/day, with higher initial dosing for severe deficiency) align with biological need and avoid the harm signals seen with intermittent mega-doses.
Routine Supplementation in Replete Adults Has Limited Yield
VITAL, DO-HEALTH, and D-Health did not show meaningful benefits on cancer, cardiovascular disease, falls, fractures, or mortality in mostly vitamin D-sufficient populations. Patient-physician decisions can de-emphasize routine prescribing where deficiency is not documented.
Pregnancy and Infancy Maintain Specific Benefit
400 IU/day for exclusively breastfed infants is supported by strong evidence preventing nutritional rickets. Maternal repletion in pregnancy carries signals for reduced pre-eclampsia and gestational diabetes, supporting use particularly where baseline status is low.
Avoid Annual or Very-High-Dose Regimens
Intermittent supraphysiologic dosing (≥60,000 IU monthly or 500,000 IU annually) has been associated with increased fall and fracture risk in older adults. When supplementation is indicated, daily moderate dosing is the more defensible approach.
Reserve 25(OH)D Testing for High-Risk Patients
Targeted screening — malabsorption, chronic kidney disease, granulomatous disease, certain medications, dark-skinned individuals with limited sun exposure, and patients with unexplained bone pain or proximal myopathy — is more defensible than routine population screening.
Set Realistic Expectations With Patients
Many patients arrive convinced of broad benefits of vitamin D supplementation. Calibrating expectations using VITAL, DO-HEALTH, and D-Health findings supports informed decisions and avoids both reflexive prescribing and overly absolutist deprescribing.
Implementation Considerations
The most common vitamin D supplementation pitfalls in primary care are reflexive 25(OH)D testing without a clinical question, prescribing intermittent mega-doses for convenience, and continuing maintenance supplementation indefinitely without a documented deficiency target. Each of these is addressable through brief workflow changes.
Evidence Grade & Bottom Line
Overall Evidence Grade: STRONG for the null effect of vitamin D supplementation on cancer, cardiovascular disease, mortality, and fractures in unselected, mostly replete adults — supported by VITAL, DO-HEALTH, D-Health, and Cochrane updates with trial sequential analysis. MODERATE for benefit in documented deficiency, pregnancy, and exclusively breastfed infants. LIMITED for fall prevention in community-dwelling older adults, with harm signals at very high intermittent doses.
Bottom Line
- Three large contemporary trials (VITAL, DO-HEALTH, D-Health) converge on the conclusion that routine vitamin D supplementation in unselected, mostly replete adults does not meaningfully reduce cancer, cardiovascular disease, fractures, falls, or all-cause mortality.
- Targeted use remains evidence-based in documented deficiency, exclusively breastfed infants, and selected pregnancy contexts where baseline status is low or risk factors are present.
- Annual or very-high-dose monthly regimens carry harm signals for falls and fractures and should generally be avoided in favor of daily moderate dosing.
- Routine 25(OH)D screening of asymptomatic adults is not supported by current USPSTF guidance; targeted screening of high-risk groups is more defensible.
- Subgroup signals from VITAL — including possible cancer benefit in Black participants and lower-BMI individuals — are hypothesis-generating and not yet a basis for differential prescribing.
Article Information & References
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Manson JE, Cook NR, Lee IM, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease (VITAL). N Engl J Med. 2019;380(1):33–44. DOI: 10.1056/NEJMoa1809944
- LeBoff MS, Chou SH, Ratliff KA, et al. Supplemental vitamin D and incident fractures in midlife and older adults. N Engl J Med. 2022;387(4):299–309. DOI: 10.1056/NEJMoa2202106
- Bischoff-Ferrari HA, Vellas B, Rizzoli R, et al. Effect of vitamin D supplementation, omega-3 fatty acid supplementation, or a strength-training exercise program on clinical outcomes in older adults: the DO-HEALTH randomized clinical trial. JAMA. 2020;324(18):1855–1868. DOI: 10.1001/jama.2020.16909
- Neale RE, Baxter C, Romero BD, et al. The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality. Lancet Diabetes Endocrinol. 2022;10(2):120–128. DOI: 10.1016/S2213-8587(21)00345-4
- Pittas AG, Dawson-Hughes B, Sheehan P, et al. Vitamin D supplementation and prevention of type 2 diabetes (D2d). N Engl J Med. 2019;381(6):520–530. DOI: 10.1056/NEJMoa1900906
- Bolland MJ, Grey A, Avenell A. Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. Lancet Diabetes Endocrinol. 2018;6(11):847–858. DOI: 10.1016/S2213-8587(18)30265-1
- Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, et al. Monthly high-dose vitamin D treatment for the prevention of functional decline: a randomized clinical trial. JAMA Intern Med. 2016;176(2):175–183. DOI: 10.1001/jamainternmed.2015.7148
- Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA. 2010;303(18):1815–1822. DOI: 10.1001/jama.2010.594
- US Preventive Services Task Force. Vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults: USPSTF recommendation statement. JAMA. 2018;319(15):1592–1599. DOI: 10.1001/jama.2018.3185
- US Preventive Services Task Force. Screening for vitamin D deficiency in adults: USPSTF recommendation statement. JAMA. 2021;325(14):1436–1442. DOI: 10.1001/jama.2021.3069
- Avenell A, Mak JC, O’Connell DL. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst Rev. 2014;4:CD000227. DOI: 10.1002/14651858.CD000227.pub4
- Bjelakovic G, Gluud LL, Nikolova D, et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev. 2014;1:CD007470. DOI: 10.1002/14651858.CD007470.pub3
- Palacios C, Kostiuk LK, Peña-Rosas JP. Vitamin D supplementation for women during pregnancy. Cochrane Database Syst Rev. 2019;7:CD008873. DOI: 10.1002/14651858.CD008873.pub4
- Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–1930. DOI: 10.1210/jc.2011-0385
- Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53–58. DOI: 10.1210/jc.2010-2704